The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing ...

Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in the treatment of relapsed or refractory haematological cancers, fundamentally altering the landscape of cancer care. By harnessing the body’s immune system, this therapy effectively targets and destroys cancer cells, demonstrating remarkable efficacy particularly in acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma. At the forefront of advancements discussed during EBMT 2024, Dr. Sridhar Chaganti highlighted pioneering strategies, including the development of allogeneic CAR T-cell therapies. These therapies not only exhibit potential in reducing Graft-versus-Host disease but also show promise in improving cell expansion, marking significant progress in overcoming treatment limitations. Moreover, innovative approaches aim to address associated side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Among these, the introduction of the JAK1 inhibitor, itacitinib, stands out as a promising avenue for mitigating adverse reactions and enhancing patient outcomes in the realm of CAR T-cell therapy

Watch haemato-oncology experts discuss updates in R/R follicular lymphoma, with a focus on CAR T-cell therapy.

The Renoir phase 3 study investigates the efficacy of combining rituximab and lenalidomide versus rituximab alone for relapsed/refractory (R/R) follicular lymphoma in elderly patients, in whom treatment options are typically limited. Lenalidomide, known for its direct anti-tumor and antiangiogenic ...

The role of transplant and biologics in mantle cell lymphoma In the first of two updates from ASH 2022, Swaminathan Iyer (University of Texas MD Anderson Cancer Center) provides an overview of the plenary session presented by Dr Martin Dreyling at ...

Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the challenges and unmet needs in the front-line treatment of Hodgkin lymphoma. Firstly, as a curable disease in around 75% of patients one challenge is finding a cure in more patients. Secondly, ...

Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study in patients with follicular lymphoma, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy . The study compared rituximab-based chemotherapy with ...